A key purpose of telehealth platforms, and other potential US partners is to efficiently connect tech product/service providers to US doctors without extensive marketing/admin costs.
Given the attractive CPT code reimbursement of $30-40 US per patient per month that is available to RSH, it will most likely make more sense to pass on some of that margin to US partners rather than extensive up front marketing/admin costs.
on top of this reimbursement fee to RSH, the doctors can be reimbursed ~$1000 US per year for each Wheezo patient - A clear point of difference vs other markets such as Aust.
A key purpose of telehealth platforms, and other potential US...
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.4¢ |
Change
0.004(13.3%) |
Mkt cap ! $36.03M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.4¢ | 3.0¢ | $36.75K | 1.184M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 224180 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 79999 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.4¢ |
Change
0.004 ( 13.3 %) |
||||
| Open | High | Low | Volume | ||
| 3.2¢ | 3.4¢ | 3.2¢ | 71127 | ||
| Last updated 14.52pm 03/05/2024 ? | |||||
| RSH (ASX) Chart |